Patents by Inventor Kunlun He
Kunlun He has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240044870Abstract: The present disclosure provides methods, reagents, compositions, systems and kits for high-throughput drug screening by using barcode molecules. In some embodiments, the method uses one step RT-PCR to simplify the experimental procedure and avoid RNA contamination in the experimental process.Type: ApplicationFiled: December 22, 2021Publication date: February 8, 2024Inventors: Kunlun HE, Zhilong JIA, Jue WU, Xinyu SONG, Yu LU, Wenqi ZHU
-
Patent number: 11628168Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: GrantFiled: June 5, 2019Date of Patent: April 18, 2023Assignees: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun He, Xiaojian Gao, Chunlei Liu, Zeyu Zhang, Xin Li, Chen Li, Yunfu Luo, Maoyi Lei, Junmiao Li, Yiwei Wang
-
Publication number: 20210393627Abstract: The present disclosure provides application of a compound in conformity with a general formula I and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease and a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: ApplicationFiled: June 5, 2019Publication date: December 23, 2021Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun HE, Xiaojian GAO, Chunlei LIU, Zeyu ZHANG, Xin LI, Chen LI, Yunfu LUO, Maoyi LEI, Junmiao LI, Yiwei WANG
-
Publication number: 20210338665Abstract: The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.Type: ApplicationFiled: June 5, 2019Publication date: November 4, 2021Applicants: CHINESE PLA GENERAL HOSPITAL, SHIJIAZHUANG SAGACITY NEW DRUG DEVELOPMENT COMPANY, LTD.Inventors: Kunlun HE, Zeyu ZHANG, Xiaojian GAO, Chunlei LIU, Xin LI, Chen LI, Wenyuan QIAN, Chundao YANG, Guanghai XU, Yiwei WANG
-
Patent number: 11032984Abstract: The present invention discloses genes and SNP markers significantly associated with lint percentage trait in cotton, and use thereof. The genes significantly associated with the lint percentage trait in cotton are genes Gh_D05G1124, Gh_D05G0313, and GhWAKL3. In the present invention, a CottonSNP63K gene array is used for genotyping, and genome re-sequencing data are analyzed to identify SNP markers significantly associated with the lint percentage trait in cotton. Moreover, the present invention also discloses use of the genes and SNP markers, which are significantly associated with the lint percentage trait in cotton, in cotton germplasm identification, breeding, or genetic diversity analysis.Type: GrantFiled: April 29, 2019Date of Patent: June 15, 2021Assignee: Institute of Cotton Research of the Chinese Academy of Agricultural SciencesInventors: Wei Li, Daigang Yang, Xiongfeng Ma, Xiaoyu Pei, Yangai Liu, Kunlun He, Fei Zhang, Zhongying Ren, Xiaojian Zhou, Wensheng Zhang, Zhenyu Wang, Chengxiang Song, Kuan Sun
-
Publication number: 20200404869Abstract: The present invention discloses genes and SNP markers significantly associated with lint percentage trait in cotton, and use thereof. The genes significantly associated with the lint percentage trait in cotton are genes Gh_D05G1124, Gh_D05G0313, and GhWAKL3. In the present invention, a CottonSNP63K gene array is used for genotyping, and genome re-sequencing data are analyzed to identify SNP markers significantly associated with the lint percentage trait in cotton. Moreover, the present invention also discloses use of the genes and SNP markers, which are significantly associated with the lint percentage trait in cotton, in cotton germplasm identification, breeding, or genetic diversity analysis.Type: ApplicationFiled: April 29, 2019Publication date: December 31, 2020Inventors: Wei Li, Daigang Yang, Xiongfeng Ma, Xiaoyu Pei, Yangai Liu, Kunlun He, Fei Zhang, Zhongying Ren, Xiaojian Zhou, Wensheng Zhang, Zhenyu Wang, Chengxiang Song, Kuan Sun
-
Patent number: 9439881Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: October 26, 2015Date of Patent: September 13, 2016Assignee: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Jie Wang, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Tang
-
Patent number: 9260384Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 14, 2010Date of Patent: February 16, 2016Assignee: Chinese PLA General HospitalInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Bai
-
Publication number: 20160038445Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: October 26, 2015Publication date: February 11, 2016Inventors: Kunlun HE, Song LI, Wu ZHONG, Juan LIU, Lili WANG, Xin LI, Guoliang HU, Jie WANG, Long LONG, Junhai XIAO, Zhibing ZHENG, Wei LI, Ruijun LI, Chunlei LIU, Jie TANG
-
Patent number: 9139543Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.Type: GrantFiled: May 10, 2013Date of Patent: September 22, 2015Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
-
Publication number: 20150119430Abstract: The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 10, 2013Publication date: April 30, 2015Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Kunlun He, Junhai Xiao, Xinbo Zhou
-
Patent number: 8884007Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 16, 2011Date of Patent: November 11, 2014Assignee: Institute of Pharmacology and Toxicology Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Lili Wang, Kunlun He, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Xin Li, Guoliang Hu
-
Patent number: 8859587Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosis.Type: GrantFiled: May 14, 2010Date of Patent: October 14, 2014Assignee: Chinese PLA General HospitalInventors: Kunlun He, Song Li, Lili Wang, Xin Li, Wu Zhong, Guoliang Hu, Jie Wang, Ruijin Li, Chunlei Liu, Junhai Xiao, Long Long, Wei Li, Hua Chen
-
Publication number: 20130158022Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 14, 2010Publication date: June 20, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Jie Wang, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Tang
-
Publication number: 20130143917Abstract: The present invention relates to an acrylamide compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, to a composition comprising the compound or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent, and to a use of the compound or the composition for prophylaxis and/or treatment of a disease or disorder associated with cardiomyocyte apoptosisType: ApplicationFiled: May 14, 2010Publication date: June 6, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Lili Wang, Xin Li, Wu Zhong, Guoliang Hu, Jie Wang, Ruijun Li, Chunlei Liu, Junhai Xiao, Long Long, Wei Li, Hua Chen
-
Publication number: 20130123300Abstract: A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 14, 2010Publication date: May 16, 2013Applicant: CHINESE PLA GENERAL HOSPITALInventors: Kunlun He, Song Li, Wu Zhong, Juan Liu, Lili Wang, Xin Li, Guoliang Hu, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Ruijun Li, Chunlei Liu, Jie Bai
-
Publication number: 20130116256Abstract: The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis.Type: ApplicationFiled: May 16, 2011Publication date: May 9, 2013Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Wu Zhong, Juan Liu, Lili Wang, Kunlun He, Long Long, Junhai Xiao, Zhibing Zheng, Wei Li, Xin Li, Guoliang Hu